Sign up
Quantellect · Analysts · Analyst Profile
Q Score Rank#136 of 388

Jason Gerberry

B of A Securities · Equity Research Analyst
ProvisionalRating since 2021No new ratings since Jun 2025

Analyst rating accuracy & track record

Jason Gerberry is an equity research analyst at B of A Securities. Quantellect has scored 23 of their stock calls across 14 companies. Their picks beat their sector 46% of the time over the next 12 months, and their price targets were reached 51% of the time within a year.

Win % vs sector
46%
PT Hit % (12mo)
51%
Avg sector-excess
−2.2%
Scored calls
23
Tickers
14
Tier
Provisional

Track record

Quantellect has scored 23 of Jason Gerberry's stock calls across 14 companies, dating back to 2021. Their rated stocks beat their own sector 46% of the time over the next 12 months. On a typical call, a Gerberry pick returned −2.2% more than its sector over the following year.

Of the scored calls, 14 were bullish (Buy) and 9 were bearish (Sell). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
PROKProKidney Corp.
Sell$1.00Jun 2025−243.5%Hit
LQDALiquidia Technologies Inc
Buy$23.00Jun 2025+381.1%Hit
TEVATeva Pharma Industries Ltd ADR
Buy$22.00May 2025+101.0%Hit
PCVXVaxcyte Inc
Buy$137.00Apr 2025+69.4%Miss
IMVTImmunovant Inc
Buy$33.00Mar 2025+16.1%Miss
TEVATeva Pharma Industries Ltd ADR
Buy$20.00Mar 2025+98.1%Hit
VTRSViatris Inc
Sell$10.00Feb 2025−69.0%Hit
IMVTImmunovant Inc
Buy$45.00Jan 2025−3.9%Miss
CPRXCatalyst Pharmaceuticals Inc
Buy$30.00Jan 2025−11.0%Miss
BHVNBiohaven Ltd.
Buy$62.00Sep 2024−63.1%Miss
PCVXVaxcyte Inc
Buy$140.00Sep 2024−61.8%Miss
GLPGGalapagos NV ADR
Sell$31.00Apr 2024+31.5%Hit
GLPGGalapagos NV ADR
Sell$31.00Mar 2024+29.4%Hit
LYRALyra Therapeutics Inc
Buy$11.00Mar 2024−98.7%Miss
CPRXCatalyst Pharmaceuticals Inc
Buy$23.00Mar 2024+31.6%Hit
VTRSViatris Inc
Sell$9.00Oct 2023−13.6%Hit
LYRALyra Therapeutics Inc
Buy$15.00Sep 2023−113.1%Miss
OCSOculis Holding AG Ordinary shares
Buy$24.00Aug 2023−27.1%Miss
OCSOculis Holding AG Ordinary shares
Buy$22.00Jun 2023−15.9%Miss
TVRDTvardi Therapeutics, Inc.
Sell$4.00May 2023+95.3%Hit
TVRDTvardi Therapeutics, Inc.
Sell$6.00Mar 2023+102.8%Hit
OGNOrganon & Co
Sell$25.00Oct 2022+31.6%Hit
BYSIBeyondSpring Inc
Sell$5.00Dec 2021+94.6%Hit
Go to

Jason Gerberry: analyst track record FAQ

Is Jason Gerberry a good stock analyst?

Yes, by track record. Jason Gerberry ranks number 136 of 388 of the analysts Quantellect scores, with a Q Score of 43 out of 100. Past results do not guarantee future ones.

What is Jason Gerberry's win rate?

Jason Gerberry's win rate is 46%. Across 23 scored calls, their rated stocks beat their sector 46% of the time over the next 12 months. On a typical call they returned −2.2% more than the sector.

What stocks and sectors does Jason Gerberry cover?

Jason Gerberry covers 14 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Jason Gerberry's price targets accurate?

Jason Gerberry's price targets are reached within 12 months 51% of the time. The base rate across all analysts Quantellect tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Quantellect scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Jason Gerberry's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Quantellect score analyst accuracy?

Quantellect scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Jason Gerberry rank among Wall Street analysts?

Jason Gerberry ranks number 136 of 388 by Q Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Quantellect calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.